Company intelligence / Profile preview

Pulnovo Medical

Ownership: Private
Development stage: Commercial

Overview

PADN-CFDA pivotal study met primary efficacy and safety endpoints as the first global RCT for a PH treatment device. PADN recognized as an innovative medical device by China NMPA in 2018 and designated a "breakthrough device" by US FDA in 2021. Market approval obtained in China; positive results reported from clinical studies; included in international guidelines.

Therapeutic areas: Cardiovascular
Modalities: DeviceRadiofrequency ablation device
Industry: Therapeutic Medical Devices

Drug pipeline

1 asset

PADN

Commercial

Indications: Pulmonary hypertension, Heart failure

Beyond the preview

Go deeper on Pulnovo Medical.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Pulnovo Medical.

Explore the full profile